Patient baseline characteristics
| . | ICANS grade 0-2 (n = 16) . | ICANS grade ≥3 (n = 10) . | Univariate P . |
|---|---|---|---|
| Age, median (range), y | 69.5 (50-82) | 64.5 (58-73) | .20 |
| Males, n (%) | 11 (69%) | 8 (80%) | .67 |
| Simplified MIPI intermediate or high risk, n (%) | 12 (75%) | 6 (60%) | .66 |
| MIPIc high-intermediate or high risk, n/total n (%) | 9/15 (60%) | 3/8 (38%) | .40 |
| History of epilepsy | 1 (6%) | 2 (20%) | .54 |
| Disease burden | |||
| Increased LDH at leukapheresis | 9 (56%) | 4 (40%) | .69 |
| Stage III-IV at leukapheresis | 14 (88%) | 8 (80%) | .63 |
| High-risk disease characteristic | |||
| Blastoid or pleomorphic morphologic characteristics of MCL, n (%) | 2 (13%) | 4 (40%) | .17 |
| Ki-67 Proliferation Index score of ≥30%, n/total n (%) | 9/15 (60%) | 4/8 (50%) | .53 |
| Known TP53 mutation or del(17p), n (%) | 2 (13%) | 4 (40%) | .17 |
| History of MCL with CNS involvement | 2 (13%) | 1 (10%) | 1.00 |
| Active MCL with CNS involvement status when starting LD chemotherapy | 1 (6%) | 0 | 1.00 |
| Previous therapies | |||
| Number of prior lines of therapy, median [range] | 4 [2-10] | 3.5 [2-8] | .61 |
| ≥3 prior lines of therapy, n (%) | 15 (94%) | 7 (70%) | .26 |
| Prior autologous SCT | 4 (25%) | 5 (50%) | .23 |
| Prior allogeneic SCT | 2 (13%) | 2 (20%) | 1.00 |
| Prior BTK inhibitor therapy, n (%) | 14 (88%) | 10 (100%) | .51 |
| r/r disease, n (%) | |||
| Refractory to most recent previous therapy | 5 (31%) | 5 (50%) | .42 |
| Relapse after most recent previous therapy | 11 (69%) | 5 (50%) | .42 |
| . | ICANS grade 0-2 (n = 16) . | ICANS grade ≥3 (n = 10) . | Univariate P . |
|---|---|---|---|
| Age, median (range), y | 69.5 (50-82) | 64.5 (58-73) | .20 |
| Males, n (%) | 11 (69%) | 8 (80%) | .67 |
| Simplified MIPI intermediate or high risk, n (%) | 12 (75%) | 6 (60%) | .66 |
| MIPIc high-intermediate or high risk, n/total n (%) | 9/15 (60%) | 3/8 (38%) | .40 |
| History of epilepsy | 1 (6%) | 2 (20%) | .54 |
| Disease burden | |||
| Increased LDH at leukapheresis | 9 (56%) | 4 (40%) | .69 |
| Stage III-IV at leukapheresis | 14 (88%) | 8 (80%) | .63 |
| High-risk disease characteristic | |||
| Blastoid or pleomorphic morphologic characteristics of MCL, n (%) | 2 (13%) | 4 (40%) | .17 |
| Ki-67 Proliferation Index score of ≥30%, n/total n (%) | 9/15 (60%) | 4/8 (50%) | .53 |
| Known TP53 mutation or del(17p), n (%) | 2 (13%) | 4 (40%) | .17 |
| History of MCL with CNS involvement | 2 (13%) | 1 (10%) | 1.00 |
| Active MCL with CNS involvement status when starting LD chemotherapy | 1 (6%) | 0 | 1.00 |
| Previous therapies | |||
| Number of prior lines of therapy, median [range] | 4 [2-10] | 3.5 [2-8] | .61 |
| ≥3 prior lines of therapy, n (%) | 15 (94%) | 7 (70%) | .26 |
| Prior autologous SCT | 4 (25%) | 5 (50%) | .23 |
| Prior allogeneic SCT | 2 (13%) | 2 (20%) | 1.00 |
| Prior BTK inhibitor therapy, n (%) | 14 (88%) | 10 (100%) | .51 |
| r/r disease, n (%) | |||
| Refractory to most recent previous therapy | 5 (31%) | 5 (50%) | .42 |
| Relapse after most recent previous therapy | 11 (69%) | 5 (50%) | .42 |
BTK, Bruton tyrosine kinase; LD, lymphodepletion; LDH, lactate dehydrogenase; MIPI, MCL International Prognostic Index; MIPIc, combined MIPI with Ki-67 Index; SCT, stem cell transplantation.